Hedera helix: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Productive cough

Adult: As effervescent tab: 50 mg bid. As syrup or solution (containing dried ivy leaf extract 0.7 g/100 mL): 5-7.5 mL bid or tid.
Child: As effervescent tab: 6-11 years 25 mg bid; ≥12 years Same as adult dose. As syrup (containing dried ivy leaf extract 0.7 g/100 mL): 2-6 years 2.5 mL bid; >6-12 years 5 mL bid or tid; ≥12 years Same as adult dose.

Contraindications

Children <2 years. Pregnancy and lactation.

Special Precautions

Patients with gastritis or gastric ulcer. Treatment with a cough medicine in children (especially under 6 years old) should be considered carefully due to potential risks and limited evidence on efficacy.

Adverse Reactions

Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
Immune system disorders: Allergic reactions (e.g. skin rash, urticaria, dyspnoea).

Monitoring Parameters

Monitor for signs or symptoms of dyspnoea, fever, bloody sputum and other persistent symptoms.

Overdosage

Symptoms: Nausea, vomiting, diarrhoea, excitation or agitation. Management: Symptomatic and supportive treatment.

Action

Description:
Mechanism of Action: Hedera helix (Araliaceae) contains saponins that have mucolytic, spasmolytic, and bronchodilatory actions. Based on studies, the saponins found in ivy leaf trigger responses in the gastric mucosa. Hence, activating the gastro-pulmonary mucokinetic vagal reflex which stimulates the bronchi to produce a watery fluid and induce expectoration.
Synonym: Ivy leaf.

Storage

Store below 25°C. Protect from light and moisture.

MIMS Class

Supplements & Adjuvant Therapy

ATC Classification

R05CA12 - Hederae helicis folium ; Belongs to the class of expectorants. Used in the treatment of wet cough.

Disclaimer: This information is independently developed by MIMS based on Hedera helix from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com